您要查找的是不是：
- OBJECTIVEA method for the determination of dissolution of fenofibrate chewable tablets in vitro was established. 目的:建立非諾貝特咀嚼片體外溶出度試驗測定方法。
- Fenofibrate obviously inhibited PAI-1 mRNA expression in adipose tissue(P<0.01). 非諾貝特治療后脂肪組織PAI-1mRNA表達明顯低于高膽固醇組(P<0.;01)。
- The risk of a first amputation was 36 percent lower among people taking fenofibrate than those taking the placebo. 初次截肢的風(fēng)險非諾貝特組較安慰劑組降低了36%25。
- Objective: To study the effects of Provastatin with Micronized Fenofibrate on HDL C and LDL C in old patients. 目的:研究普伐他汀和微?；侵Z貝特對老年人高密度脂蛋白膽固醇(HDL-C)和低密度脂蛋白膽固醇(LDL-C)的作用。
- Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. 非諾貝特顯著(zhù)降低HDL膽固醇水平較低患者或高血壓患者的CVD事件。
- CONCLUSION:micronised fenofibrate is bene ficial on adjusting lipid level and blood viscosity. 結論：微?；侵Z貝特能有效降低高血脂，同時(shí)明顯改善了病人的高粘血癥。
- Methods: 49 elderly patients with hyperlipoproteinemia were randomly divided into two groups: 27 in Provastatin group;22 in Fenofibrate group. 方法:49例混合型高血脂的老年患者隨機分成兩組,27例服用普伐他汀,22例服用微?；侵Z貝特。
- Pravastatin, simvastatin, atorvastatin, fluvastatin, gemfibrozil and fenofibrate had a confirmed effect in secondary prevention. 吉非貝齊一級預防雖降低心血管的死亡率,但不降低總死亡率;
- To study the effects ofmicronised fenofibrate on serum lipid level and hemorheologic changes in patientswith primary hyperli pidemia. 目的：觀(guān)察微?；侵Z貝特的降血脂療效及是否有改善血液流變性的作用。
- For hypertension and hyperlipidaemia consider the use of losartan and fenofibrate, respectively (both have modest uricosuric effects). 對于有高血壓和高脂血癥患者可分別考慮用氯沙坦和非諾貝特（兩者均有一定促進(jìn)尿酸排泄的作用）。
- The study found virtually no difference in the risk for amputations above the ankle between those who did and did not take fenofibrate. 研究發(fā)現踝以上截肢風(fēng)險在服用非諾貝特組和非服用非諾貝特組之間并無(wú)顯著(zhù)差異。
- Objective To research the effect of different serum lipid adjustment drugs, Simvastatin and Fenofibrate, on hyperlipidemic fatty liver. 目的探討不同作用機制的調脂藥（非諾貝特和辛伐他?。Ω咧Y性脂肪肝的作用。
- The fenofibrate micronized powders were prepared using lactose and MCC as the main expicients for preparation of fenofibrate tablets. 以乳糖和微晶纖維素作為主要輔料制備非諾貝特的微粉化物,并以此制備片劑,輔以預膠化淀粉調節片劑的溶出度。
- The study included 9,795 people, ages 50 to 75, who took either 200 milligrams of fenofibrate or a placebo daily for five years. 該研究樣本為9，795人，年齡50至75歲，每天服用200毫克非諾貝特或安慰劑，持續五年。
- Methods 32 male New Zealand white rabbits were divided into fenofibrate group one(50 ?/?/d), fenofibrate group two(25 ?/?/d)and control group, there were 8 rabbits in each groups. 方法 將 32 只雄性新西蘭白兔隨機分為非諾貝特 1 組(50 ?/?/d)、非諾貝特 2 組(25 ?/?/d)、阿托伐他汀組(5 ?/?/d)及對照組,每組各 8 只。
- Similarly, fenofibrate and the combination (but not simvastatin) significantly increased the percentage of buoyant LDL cholesterol constituting total LDL cholesterol. 類(lèi)似的，非諾貝特和聯(lián)合治療顯著(zhù)升高有浮力的LDL在總LDL中的比例。
- The study also found that people in the fenofibrate group had a 47 percent lower risk of amputations below the ankle and without large-vessel disease in the amputated limb. 研究還發(fā)現非諾貝特組踝以下截肢風(fēng)險降低47%25，所截肢內其無(wú)大血管病變。
- Objective To investigate the effects of micronized fenofibrate on low density lipoprotein (LDL) subfraction profiles in type IV hyperlipidemic subjects. 目的觀(guān)察微?；侵Z貝特對IV型高脂血癥患者血清低密度脂蛋白（LDL）亞組份再分布的作用。
- Combination therapy reduced dense VLDL cholesterol significantly more than did fenofibrate or simvastatin monotherapy, the investigators found. Simvastatin lowered intermediate density lipoprotein (IDL) cholesterol significantly more than did fenofibrate. 研究者發(fā)現，聯(lián)合治療相對于但用非諾貝特或辛伐他汀顯著(zhù)的降低極低密度脂蛋白膽固醇的密度。辛伐他汀比非諾貝特降低中等密度脂蛋白膽固醇的作用顯著(zhù)。
- Fenofibrate 20 mg/kg was given daily to the treated group. OGTT was performed at the age of 8,16 and 24 wks. Blood glucose,serum lipids and 24 h urine albumin excretion(UA) were investigated. 每日分別以20 mg/kg的非諾貝特及等量的蒸餾水灌胃,8、16、24周行OGTT,測定血糖、血脂及24 h尿白蛋白(24 h UAlb)。
